Boryung Pharm (003850.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7003850005

Price
8,780.00 KRW
Market cap
741.74 bn KRW
P/E (2025)
11.54
P/S (2025)
0.73
Dividend yield
1.82 %
Net margin
6.32 %
Return on equity (ROE)
7.61 %
Return on assets (ROA)
4.63 %

Boryung Pharm financials

Fiscal year20242025
Revenue1.02 tn KRW1.02 tn KRW
Gross profit363.36 bn KRW372.28 bn KRW
Operating income70.47 bn KRW65.07 bn KRW
EBIT71.96 bn KRW81.42 bn KRW
Net income69.63 bn KRW64.30 bn KRW
Diluted EPS – continuing operations829.33 KRW761.16 KRW

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Boryung Pharm

Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.